Literature DB >> 2787641

Immunohistochemical analysis of lymphoid and macrophage cell subsets and their immunologic activation markers in temporal arteritis. Influence of corticosteroid treatment.

M C Cid1, E Campo, G Ercilla, A Palacin, J Vilaseca, J Villalta, M Ingelmo.   

Abstract

To determine the phenotype of infiltrating mononuclear cells in patients with temporal arteritis (TA), we performed immunohistochemical studies on temporal artery biopsy specimens from 24 patients with biopsy-proven TA. Interdigitating reticulum cells (IRC) were observed in 41% of the patients; disease duration was significantly shorter in these patients than in patients lacking IRC (mean 1.5 months versus 3.8 months). Infiltrating cells consisted predominantly of HLA-DR-expressing macrophages and T lymphocytes, especially of the CD4 subset. There were few B cells and no K cells. No relationship between cellular distribution and disease duration or treatment was found. Interleukin-2 receptor expression was observed in 87.5% of biopsy specimens obtained prior to or within the first 4 days of treatment with prednisone, but in only 14% of specimens obtained later. The presence of IRC in patients with TA suggests an autoimmune reaction directed against an antigenic substance that resides in the arterial wall and is presented and processed in situ. DR-expressing macrophages activated by CD4+ T lymphocytes may contribute to arterial damage in TA. Corticosteroids do not modify cellular distribution but induce important functional changes, as demonstrated by the disappearance of interleukin-2 receptor expression in patients treated for more than 4 days.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787641

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  21 in total

1.  Analysis of adhesion molecules in the immunopathogenesis of giant cell arteritis.

Authors:  S O Wawryk; H Ayberk; A W Boyd; J Rode
Journal:  J Clin Pathol       Date:  1991-06       Impact factor: 3.411

2.  Giant cell arteritis.

Authors:  J P O'Brien; W Regan; E G Cleary
Journal:  J Clin Pathol       Date:  1991-12       Impact factor: 3.411

3.  Von Willebrand factor in the outcome of temporal arteritis.

Authors:  M C Cid; J Monteagudo; J Oristrell; J Vilaseca; L Pallarés; R Cervera; C Font; J Font; M Ingelmo; A Urbano-Márquez
Journal:  Ann Rheum Dis       Date:  1996-12       Impact factor: 19.103

Review 4.  Updates in the Diagnosis and Management of Giant Cell Arteritis.

Authors:  Surabhi Uppal; Mohanad Hadi; Sheetal Chhaya
Journal:  Curr Neurol Neurosci Rep       Date:  2019-08-08       Impact factor: 5.081

5.  Giant cell vasculitis is a T cell-dependent disease.

Authors:  A Brack; A Geisler; V M Martinez-Taboada; B R Younge; J J Goronzy; C M Weyand
Journal:  Mol Med       Date:  1997-08       Impact factor: 6.354

Review 6.  Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities.

Authors:  Christian Dejaco; Elisabeth Brouwer; Justin C Mason; Frank Buttgereit; Eric L Matteson; Bhaskar Dasgupta
Journal:  Nat Rev Rheumatol       Date:  2017-09-14       Impact factor: 20.543

7.  Peripheral blood lymphocyte subsets in polymyalgia rheumatica.

Authors:  A Uddhammar; G Roos; B Näsman; S R Dahlqvist
Journal:  Clin Rheumatol       Date:  1995-01       Impact factor: 2.980

8.  T lymphocytes in giant cell arteritic lesions are polyclonal cells expressing alpha beta type antigen receptors and VLA-1 integrin receptors.

Authors:  C Schaufelberger; S Stemme; R Andersson; G K Hansson
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

9.  Histological parameters helpful in recognising steroid-treated temporal arteritis: an analysis of 35 cases.

Authors:  Ramon L Font; Venkatesh C Prabhakaran
Journal:  Br J Ophthalmol       Date:  2006-09-20       Impact factor: 4.638

10.  Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis.

Authors:  C M Weyand; A D Wagner; J Björnsson; J J Goronzy
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.